MeSH term
Frequency | Condition_Probility | Acute Disease | 52 | 2.0 |
Base Sequence | 53 | 0.0 |
Chromosome Breakage/genetics | 6 | 9.0 |
Chromosome Mapping | 30 | 0.0 |
Chromosomes, Human, Pair 11/*genetics | 28 | 11.0 |
Chromosomes, Human, Pair 3/genetics | 2 | 1.0 |
DNA Topoisomerases, Type II/*metabolism | 5 | 26.0 |
DNA-Binding Proteins/*genetics | 99 | 5.0 |
GTP-Binding Proteins/*genetics | 5 | 4.0 |
Humans | 229 | 0.0 |
In Situ Hybridization, Fluorescence | 38 | 1.0 |
Infant | 50 | 0.0 |
Leukemia, Myeloid/*genetics | 24 | 16.0 |
Molecular Sequence Data | 75 | 0.0 |
*Proto-Oncogenes | 151 | 23.0 |
Research Support, Non-U.S. Gov't | 173 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 95 | 0.0 |
*Transcription Factors | 122 | 7.0 |
Translocation, Genetic/*genetics | 24 | 11.0 |
X Chromosome/*genetics | 3 | 0.0 |
Chromosomes, Human, Pair 11 | 18 | 4.0 |
Chromosomes, Human, Pair 17 | 4 | 1.0 |
*GTP Phosphohydrolases | 3 | 33.0 |
Gene Rearrangement | 23 | 5.0 |
Leukemia, Myelomonocytic, Acute/*genetics | 8 | 32.0 |
Male | 101 | 0.0 |
Middle Aged | 55 | 0.0 |
Oncogene Proteins, Fusion/*genetics | 23 | 12.0 |
RNA, Messenger/genetics | 7 | 0.0 |
Translocation, Genetic | 39 | 4.0 |
Oligonucleotide Array Sequence Analysis/methods | 2 | 2.0 |
Prognosis | 15 | 0.0 |
Recurrence | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 19 | 0.0 |
Risk Factors | 4 | 0.0 |
Aged | 53 | 0.0 |
Aged, 80 and over | 20 | 0.0 |
Child, Preschool | 38 | 0.0 |
Chromosome Aberrations | 11 | 2.0 |
Female | 94 | 0.0 |
*Gene Amplification | 6 | 1.0 |
Amino Acid Motifs | 6 | 0.0 |
Amino Acid Sequence | 43 | 0.0 |
Animals | 51 | 0.0 |
COS Cells | 4 | 0.0 |
Cell Line | 17 | 0.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Cells, Cultured | 5 | 0.0 |
Conserved Sequence | 7 | 0.0 |
DNA-Binding Proteins/genetics | 15 | 1.0 |
Mice | 32 | 0.0 |
Mice, Inbred C57BL | 6 | 0.0 |
Mice, SCID | 2 | 0.0 |
Protein Structure, Tertiary | 17 | 0.0 |
Sequence Alignment | 14 | 0.0 |
Trans-Activation (Genetics) | 7 | 0.0 |
Transcription Factors/chemistry/*genetics | 2 | 2.0 |
Transduction, Genetic | 2 | 0.0 |
Sequence Homology, Amino Acid | 18 | 0.0 |
Species Specificity | 4 | 0.0 |
Zinc Fingers | 15 | 2.0 |
DNA-Binding Proteins/genetics/*metabolism | 3 | 0.0 |
Gene Expression | 6 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Protein Binding | 14 | 0.0 |
Proto-Oncogenes/genetics | 3 | 9.0 |
Survival Rate | 2 | 0.0 |
Leukemia, Pre-B-Cell/genetics | 2 | 28.0 |
Oncogene Proteins, Fusion/genetics | 7 | 7.0 |
Translocation, Genetic/genetics | 4 | 4.0 |
*Chromosomes, Human, Pair 11 | 52 | 8.0 |
Chromosomes, Human, Pair 4 | 8 | 6.0 |
Cloning, Molecular | 26 | 0.0 |
Nuclear Proteins/*genetics | 10 | 1.0 |
Polymerase Chain Reaction/*methods | 5 | 0.0 |
*Translocation, Genetic | 57 | 6.0 |
Adult | 63 | 0.0 |
Karyotyping | 41 | 2.0 |
*Chromosome Aberrations | 18 | 3.0 |
Chromosome Painting | 2 | 4.0 |
Gene Amplification/*genetics | 5 | 4.0 |
Genes, myc | 2 | 0.0 |
*In Situ Hybridization, Fluorescence | 8 | 5.0 |
Karyotyping/methods | 3 | 11.0 |
Leukemia, Myelocytic, Acute/*genetics | 18 | 16.0 |
Myelodysplastic Syndromes/*genetics | 5 | 7.0 |
Child | 37 | 0.0 |
Chromosomes, Human, Pair 10/*genetics | 2 | 1.0 |
DNA, Neoplasm/genetics | 15 | 1.0 |
Gene Fusion | 9 | 9.0 |
*Gene Rearrangement | 21 | 8.0 |
Infant, Newborn | 12 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 15 | 0.0 |
Transcription Factors/metabolism | 3 | 0.0 |
Breast/*pathology | 2 | 11.0 |
Cytodiagnosis/methods | 2 | 16.0 |
Diagnosis, Differential | 5 | 0.0 |
English Abstract | 2 | 0.0 |
Mucocele/*pathology | 2 | 100.0 |
Binding Sites | 8 | 0.0 |
DNA Methylation | 4 | 0.0 |
DNA-Binding Proteins/*chemistry/genetics/*metabolism | 2 | 3.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
Substrate Specificity | 3 | 0.0 |
*Chromosome Deletion | 2 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Telomere/genetics | 2 | 3.0 |
Cell Lineage | 2 | 0.0 |
Comparative Study | 19 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Genes, Homeobox | 2 | 2.0 |
Immunophenotyping | 10 | 0.0 |
Neoplasm Proteins/biosynthesis/genetics | 2 | 1.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
*Adaptor Proteins, Signal Transducing | 4 | 0.0 |
Dimerization | 4 | 0.0 |
*Muscle Proteins | 2 | 0.0 |
DNA-Binding Proteins/chemistry/*genetics/*metabolism | 2 | 5.0 |
Hematopoietic Stem Cells/metabolism | 2 | 1.0 |
Models, Genetic | 7 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Leukemia, Monocytic, Acute/*genetics | 8 | 44.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
Chromosomes, Human, Pair 11/genetics | 11 | 5.0 |
Leukemia, Myelocytic, Acute/diagnosis/*genetics | 2 | 50.0 |
Predictive Value of Tests | 2 | 0.0 |
Sensitivity and Specificity | 7 | 0.0 |
Adolescent | 36 | 0.0 |
*Chromosome Disorders | 4 | 5.0 |
Fusion Proteins, bcr-abl/genetics | 2 | 4.0 |
In Situ Hybridization, Fluorescence/methods | 2 | 2.0 |
Leukemia, Lymphocytic, Acute, L1/*genetics | 3 | 7.0 |
Blotting, Southern | 22 | 0.0 |
Chromosome Banding | 9 | 1.0 |
*Gene Deletion | 3 | 0.0 |
Leukemia, Lymphocytic, Acute/*genetics | 17 | 20.0 |
Proto-Oncogenes/*genetics | 5 | 6.0 |
Transcription Factors/*genetics | 17 | 0.0 |
*Chromosome Breakage | 4 | 11.0 |
Chromosomes, Human, Pair 11/*genetics/ultrastructure | 9 | 50.0 |
Combined Modality Therapy | 3 | 0.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Neoplasms, Second Primary/chemically induced/*genetics | 4 | 66.0 |
Nuclear Proteins/genetics | 4 | 1.0 |
*Recombination, Genetic | 2 | 0.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Leukocyte Count | 2 | 0.0 |
Remission Induction | 4 | 0.0 |
Tumor Cells, Cultured | 31 | 0.0 |
U937 Cells | 2 | 0.0 |
DNA Primers | 6 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Sequence Analysis, DNA | 7 | 0.0 |
Transcription Factors/genetics | 9 | 1.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
*Neoplasm Proteins | 9 | 1.0 |
*Peptide Elongation Factors | 3 | 25.0 |
Fatal Outcome | 4 | 0.0 |
*Chromosomes, Human, Pair 4 | 11 | 5.0 |
Inversion, Chromosome | 2 | 3.0 |
DNA Damage | 3 | 0.0 |
Oncogene Proteins/genetics | 2 | 2.0 |
*Protein-Tyrosine Kinase | 2 | 0.0 |
*Proto-Oncogene Proteins | 3 | 0.0 |
Cytogenetic Analysis | 2 | 1.0 |
Great Britain | 2 | 0.0 |
Pregnancy | 4 | 0.0 |
*Gene Duplication | 5 | 3.0 |
Proto-Oncogene Proteins/*genetics | 5 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 3 | 0.0 |
DNA-Binding Proteins/*genetics/metabolism | 8 | 1.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Gene Targeting | 2 | 0.0 |
K562 Cells | 2 | 0.0 |
DNA, Complementary/genetics | 7 | 0.0 |
Rats | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Chromosome Disorders | 8 | 2.0 |
Cytogenetic Analysis/methods | 2 | 12.0 |
Leukemia, Myeloid/drug therapy/*genetics | 3 | 30.0 |
Nucleic Acid Hybridization/methods | 2 | 2.0 |
Cell Nucleus/genetics/metabolism | 2 | 5.0 |
DNA-Binding Proteins/chemistry/genetics/*metabolism | 2 | 1.0 |
Plasmids | 2 | 0.0 |
Alternative Splicing/genetics | 2 | 1.0 |
Chromosome Breakage | 5 | 6.0 |
Exons | 11 | 0.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 4 | 0.0 |
Chromosomes, Human, Pair 4/*genetics | 2 | 2.0 |
DNA-Binding Proteins/chemistry/*genetics | 2 | 2.0 |
Leukemia/*genetics | 15 | 12.0 |
Neoplasm Proteins/genetics | 4 | 0.0 |
Leukemia, Lymphocytic/*genetics | 3 | 15.0 |
DNA-Binding Proteins/biosynthesis/*genetics | 2 | 1.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Bone Marrow Transplantation | 4 | 1.0 |
Polymerase Chain Reaction | 19 | 0.0 |
Whole-Body Irradiation/adverse effects | 2 | 22.0 |
Blotting, Northern | 5 | 0.0 |
DNA, Complementary/chemistry/genetics | 2 | 0.0 |
Cell Nucleus/chemistry | 2 | 1.0 |
Transfection | 8 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Survival Analysis | 7 | 0.0 |
Transcription, Genetic | 6 | 0.0 |
DNA Probes/genetics | 2 | 1.0 |
In Situ Hybridization, Fluorescence/*methods | 3 | 3.0 |
Gene Dosage | 2 | 0.0 |
Alleles | 2 | 0.0 |
Exons/genetics | 2 | 0.0 |
Nucleic Acid Conformation | 4 | 0.0 |
Reproducibility of Results | 3 | 0.0 |
Chromosome Deletion | 4 | 0.0 |
DNA Probes | 4 | 0.0 |
Treatment Outcome | 4 | 0.0 |
*Chromosomes, Human, Pair 6 | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Hela Cells | 3 | 0.0 |
Leukemia, Myeloid/genetics | 3 | 8.0 |
Mutation/genetics | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 3 | 0.0 |
Disease-Free Survival | 4 | 0.0 |
Trisomy | 4 | 3.0 |
*Cytoskeletal Proteins | 3 | 2.0 |
Homeodomain Proteins/genetics/*metabolism | 2 | 1.0 |
Macromolecular Substances | 3 | 0.0 |
Multigene Family | 2 | 0.0 |
Organ Specificity | 3 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
src Homology Domains | 2 | 0.0 |
Chromosome Aberrations/*genetics | 4 | 2.0 |
Chromosomes, Human, Pair 6/*genetics | 3 | 2.0 |
Staining and Labeling/methods | 2 | 1.0 |
Neoplasm Proteins/*genetics | 7 | 0.0 |
Receptors, Retinoic Acid/*genetics | 2 | 3.0 |
DNA Topoisomerases, Type II/*antagonists & inhibitors | 6 | 25.0 |
Etoposide/adverse effects | 3 | 33.0 |
Time Factors | 7 | 0.0 |
*Chromosomes, Human, Pair 1 | 2 | 0.0 |
Blotting, Western | 4 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Gene Deletion | 5 | 0.0 |
Mutagenesis | 4 | 0.0 |
Introns | 4 | 0.0 |
Consensus Sequence | 3 | 0.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
Histone Deacetylases/*metabolism | 2 | 1.0 |
Homeodomain Proteins/genetics | 3 | 1.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
*Trans-Activators | 3 | 0.0 |
*Apoptosis | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
Mutation | 5 | 0.0 |
Oncogene Proteins, Fusion/*metabolism | 2 | 10.0 |
Cell Line, Tumor | 4 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Homeodomain Proteins/biosynthesis/*genetics | 2 | 9.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Genes, Structural/*genetics | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
*Genes, p53 | 2 | 0.0 |
*Mutation | 3 | 0.0 |
Neoplasms, Second Primary/*genetics | 2 | 9.0 |
*Gene Expression Regulation, Leukemic | 3 | 3.0 |
*Genes, Homeobox | 2 | 0.0 |
Homeodomain Proteins/*genetics | 4 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*adverse effects | 4 | 9.0 |
*Chromosomes, Human, Pair 17 | 2 | 0.0 |
Drosophila/genetics | 4 | 3.0 |
Leukemia, Myeloid/*chemically induced/*genetics | 2 | 50.0 |
Biological Markers | 2 | 0.0 |
Chromosomes, Human, Pair 9/*genetics | 2 | 1.0 |
Mutagenesis, Insertional/*genetics | 2 | 6.0 |
Drosophila | 2 | 0.0 |
*Drosophila Proteins | 4 | 0.0 |
Gene Library | 2 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Gene Expression Regulation, Leukemic | 5 | 5.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 2 | 1.0 |
*Nuclear Proteins | 2 | 0.0 |
Genes, Insect | 2 | 3.0 |
Mice, Knockout | 2 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Zinc Fingers/genetics | 6 | 3.0 |
Case-Control Studies | 2 | 0.0 |
Interviews | 2 | 4.0 |
Chromosomes, Human/genetics | 2 | 4.0 |
Recombination, Genetic | 2 | 0.0 |
Leukemia/*genetics/pathology | 4 | 23.0 |
DNA Topoisomerases, Type II/antagonists & inhibitors | 5 | 18.0 |
Leukemia, Lymphocytic, Acute/drug therapy/*genetics | 2 | 20.0 |
Follow-Up Studies | 4 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Bone Marrow/pathology | 6 | 1.0 |
Leukemia, Lymphocytic, Acute/genetics | 5 | 16.0 |
Leukemia, Myelomonocytic, Acute/*genetics/pathology | 2 | 40.0 |
RNA Splicing | 2 | 0.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Leukemia, Myelocytic, Acute/chemically induced/*genetics | 2 | 66.0 |
*Chromosomes, Human, Pair 22 | 2 | 0.0 |
Membrane Glycoproteins/genetics | 2 | 1.0 |
*Exons | 2 | 0.0 |
*Multigene Family | 6 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Restriction Mapping | 12 | 0.0 |
Nuclear Proteins/*genetics/metabolism | 2 | 1.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Genes, Tumor Suppressor | 2 | 0.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
DNA, Neoplasm/analysis | 5 | 0.0 |
Hamsters | 2 | 0.0 |
Hybrid Cells | 3 | 0.0 |
*Chromosomes, Human, Pair 16 | 2 | 0.0 |
Cell Transformation, Neoplastic | 4 | 0.0 |
Leukemia, Myeloid/*genetics/pathology | 2 | 7.0 |
Chromosomes, Human, Pair 9 | 2 | 1.0 |
Heterozygote | 2 | 0.0 |
Antineoplastic Agents/*adverse effects | 2 | 3.0 |
Etoposide/pharmacology | 2 | 1.0 |
Leukemia/genetics | 2 | 4.0 |
Leukemia, Lymphocytic/genetics | 3 | 27.0 |
Recombinant Fusion Proteins/biosynthesis | 3 | 0.0 |
Gene Amplification | 2 | 0.0 |
Blood Group Antigens | 2 | 5.0 |
Cell Line/drug effects | 2 | 4.0 |
Chimeric Proteins/biosynthesis | 2 | 4.0 |
Protein Structure, Secondary | 2 | 0.0 |
Cell Differentiation | 4 | 0.0 |
Leukemia/*etiology | 2 | 40.0 |
Leukemia, Myeloid/*etiology/genetics | 2 | 100.0 |
Chromosomes, Human, Pair 5/*genetics | 2 | 2.0 |
Immunohistochemistry | 3 | 0.0 |
Chromosomes, Human, Pair 11/genetics/*ultrastructure | 2 | 50.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Chromosomes, Human, Pair 11/*ultrastructure | 3 | 13.0 |
Leukemia, Myelocytic, Acute/genetics | 2 | 6.0 |
Protein Conformation | 2 | 0.0 |
Zinc Fingers/*genetics | 3 | 1.0 |
*Chromosomes, Human, Pair 10 | 4 | 2.0 |
Chromosomes, Human, Pair 19 | 3 | 1.0 |
Genes, Structural | 3 | 0.0 |
Neoplasms/drug therapy/radiotherapy | 2 | 66.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Leukemia, Monocytic, Acute/genetics | 2 | 33.0 |
Life Tables | 2 | 1.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
DNA/metabolism | 2 | 0.0 |
DNA, Neoplasm/isolation & purification | 2 | 6.0 |
*Genetic Markers | 2 | 0.0 |
Lymphoma/genetics | 3 | 12.0 |
Chimeric Proteins/*biosynthesis | 2 | 28.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
DNA Topoisomerases, Type II/metabolism | 2 | 9.0 |
RNA, Messenger | 2 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
*Chromosomes, Human, Pair 12 | 2 | 0.0 |
*Genes | 2 | 0.0 |
DNA-Binding Proteins/chemistry/*metabolism | 2 | 1.0 |
Cohort Studies | 2 | 0.0 |
Gene Expression Profiling/*methods | 2 | 2.0 |
Leukemia, Myelocytic, Acute/*genetics/pathology | 2 | 6.0 |
Models, Molecular | 2 | 0.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
*Gene Expression | 2 | 0.0 |
Trans-Activators/genetics | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
DNA-Binding Proteins/*genetics/*metabolism | 2 | 1.0 |
Gene Duplication | 2 | 1.0 |
Gene Expression Regulation | 3 | 0.0 |
Antigens, CD/immunology | 2 | 0.0 |
Bone Marrow/metabolism | 2 | 1.0 |
Saccharomyces cerevisiae Proteins/genetics | 2 | 5.0 |
Chromosomes, Human, Pair 15/*genetics/ultrastructure | 2 | 50.0 |
